TGFB1 and metabolic syndrome: Our results demonstrate that treatment with rosiglitazone alone is able to improve the hyperglycemia, dyslipidemia, and to decrease TNF-α, TGF-β, collagen-I and collagen-III and increased MMP-2 but within a minimal effect.